ModuleTitle@CompanyName@Symbol@Address@Phone@Industry@Sector@Region@CompanyDescription@KeyExecutives@Number_of_employees@Subsidiaries
Company Description@DexCom, Inc.@DXCM@6340 SEQUENCE DRIVE, SAN DIEGO, California, 92121, United States of America@8582000200@Medical/Dental Instruments@Health Care@North America@"We are a medical device company primarily focused on the design, development and
commercialization of continuous glucose monitoring, or CGM, systems for use by
people with diabetes and by healthcare providers. We received approval from the
United States (U.S.) Food and Drug Administration, or FDA, and commercialized
our first product in 2006. We launched our latest generation system, the DexCom
G6® integrated Continuous Glucose Monitoring System, or G6, in 2018. Unless the
context requires otherwise, the terms ""we,"" ""us,"" ""our,"" the ""company,"" or
""DexCom"" refer to DexCom, Inc. and its subsidiaries.
Products
DexCom G6® 
In March 2018, we obtained marketing authorization from the FDA for the G6 via
the de novo process.&nbsp;&nbsp;... <a href=""http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f13%2f0001093557-20-000029.html#FIS_BUSINESS"" target=""_blank"">More</a> ...&nbsp;&nbsp;
"@[('Andrew K. Balo', 'EVP-Clinical Affairs, Regulatory Strategies'), ('Jacob Leach', 'Chief Technology Officer'), ('Kevin Ronald Sayer', 'Chairman, President & Chief Executive Officer'), ('Quentin S. Blackford', 'Chief Operating & Financial Officer'), ('Shelly R. Selvaraj', 'Senior Vice President-Information Technology')]@['3,900']@['NO INFO']
